Background. Both epidemic and pandemic influenza are major public health concerns, but current standard treatment limits its usage by 48 hours from onsets. Furthermore, no antiviral drug has been shown to definitively reduce serious complications, hospitalization, or mortality in a randomized clinical trial. S-033188 is an orally available small molecule inhibitor of cap-dependent endonuclease that is essential for transcription and replication of influenza A and B virus. In this study, we evaluated the efficacy of delayed dosing of S-033188, either as single agent or in combination with oseltamivir, in mice infected with lethal doses of influenza A virus.
Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with
Background. VL-2397 is a novel antifungal agent in clinical development for treatment of invasive aspergillosis (IA). The analysis objectives were to: 1) develop a population PK model using data from a Phase 1 trial in healthy adult volunteers, 2) define the PK-PD driver of efficacy in a mouse model of IA, and 3) conduct PK-PD target attainment analyses to aid in Phase 2 dose selection for patients with IA.
Methods. Data from two studies were used: a dose fractionation study in a mouse model of IA and a Phase 1 study in healthy adult volunteers receiving single-and multiple-ascending doses of intravenous (IV) VL-2397 ranging from 3 mg to 1200 mg daily. Mouse lung fungal burden (LFB) measured on Day 4 after infection with Aspergillus fumigatus FP1305 (MIC of 1 µg/mL) was used to assess the predictive value of three measures of VL-2397 exposure: total-drug AUC 0-24 :MIC (tAUC 0-24 :MIC), total-drug C max :MIC, and total-drug %T>MIC; total drug was used because serum protein binding is similar in mice and humans. A population PK model for VL-2397 in humans was developed in NONMEM v7.1.2 and formed the basis of Monte Carlo simulations. The model was also fit to mouse PK data to estimate the VL-2397 exposure in mice.
Results. VL-2397 concentration-time data in humans revealed nonlinear PK behavior consistent with highly-bound compounds. A robust fit to the data was obtained using a two-compartment model with linear elimination and concentration-dependent binding in both central and peripheral compartments. The results of the dose fractionation study suggested that tAUC 0-24 :MIC was the most predictive (r 2 = 0.713) driver of efficacy, with a value of 21.8 on Day 1 associated with a 2-log reduction in LFB on Day 4. Comparisons of the simulated VL-2397 tAUC 0-24 :MIC on Day 1 in humans receiving daily dosing regimens of 300 mg, 600 mg, and 900 mg of VL-2397 to the 2-log target (figure) suggested that a dose of 600 mg Q24 would provide robust (99.9%) PK-PD target attainment up to an A. fumigatus MIC of 2 µg/mL. 
Conclusion.
The PK-PD driver of efficacy for VL-2397 was tAUC 0-24 :MIC and a value of 21.8 was associated with a 2-log reduction in LFB in a mouse model of IA. PK-PD target attainment assessments indicate that a VL-2397 dose of 600 mg IV Q24 will provide adequate target attainment up to an MIC of 2 µg/mL.
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Background.
Clostridium difficile infection (CDI) is the most common cause of diarrhea in hospitals. The only available intravenous (IV) therapy for CDI is metronidazole, which showed only a 52.4% cure rate in a prospective observational study. DS11960558 is a water-soluble prodrug of DS-2969b, which is a novel GyrB inhibitor in clinical development for oral treatment of CDI and has been found to be safe and tolerable in its phase 1 study. The in vivo efficacy and physicochemical, pharmacokinetic, and toxicological profiles of the prodrug were evaluated in this study.
Methods. Efficacy was evaluated in a hamster CDI model. The animals were primed with a single subcutaneous (SC) clindamycin injection. Then, the infection was induced by oral gavage of C. difficile 2009155 (NAP1/027) spores. Treatment was initiated 6 hours post infection and repeated for 5 days. The animals were observed for survival and death once daily for 35 days. The physicochemical, pharmacokinetic, and toxicological profiles were evaluated by standard methods.
Results. SC administration of the prodrug showed comparable and superior efficacy to oral (PO) administration of DS-2969b and the combination of metronidazole (SC) and vancomycin (PO), respectively, in the hamster CDI model (Figure 1) . The solubility of DS-2969b was 0.4 mg/mL while that of the prodrug was much higher, >100 mg/mL. The prodrug was converted to DS-2969a (free form of DS-2969b) rapidly after IV administration, and the conversion ratio was >80% (Figure 2 ). The main metabolites in rat urine and feces were oxidized forms of DS-2969a, and there were no prodrug-specific metabolites. Fecal excretion of DS-2969a was similar between IV administration of the prodrug and PO administration of DS-2969b. Most of the radioactivity was recovered after IV administration of the 14 C-labeled prodrug in rats. The radioactivity was distributed widely in most tissues including the intestinal lumen, similar to the distribution of DS-2969b in rats. In safety pharmacology, genotoxicity, and rat 14-day repeated dose toxicity studies, the prodrug as well as DS-2969b did not show any significant findings.
Conclusion. These results support development of DS11960558 as an alternative IV treatment option for CDI patients who cannot take medicine orally.
